Your browser is no longer supported. Please, upgrade your browser.
Settings
BOLD Audentes Therapeutics, Inc. daily Stock Chart
BOLD [NASD]
Audentes Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.72 Insider Own1.30% Shs Outstand41.29M Perf Week5.69%
Market Cap1.02B Forward P/E- EPS next Y-3.92 Insider Trans-19.86% Shs Float39.10M Perf Month0.57%
Income-98.10M PEG- EPS next Q-0.92 Inst Own100.00% Short Float6.73% Perf Quarter5.19%
Sales- P/S- EPS this Y52.40% Inst Trans9.26% Short Ratio5.06 Perf Half Y-25.99%
Book/sh8.31 P/B2.97 EPS next Y-13.60% ROA-37.50% Target Price38.33 Perf Year-24.68%
Cash/sh6.80 P/C3.64 EPS next 5Y3.90% ROE-40.50% 52W Range17.95 - 46.18 Perf YTD15.95%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-46.47% Beta-
Dividend %- Quick Ratio14.80 Sales past 5Y- Gross Margin- 52W Low37.72% ATR1.15
Employees152 Current Ratio14.80 Sales Q/Q- Oper. Margin- RSI (14)56.46 Volatility3.37% 4.87%
OptionableYes Debt/Eq0.00 EPS Q/Q-10.30% Profit Margin- Rel Volume0.48 Prev Close23.91
ShortableYes LT Debt/Eq0.00 EarningsMar 07 AMC Payout- Avg Volume519.91K Price24.72
Recom2.10 SMA203.15% SMA506.55% SMA200-22.09% Volume249,521 Change3.39%
Jan-11-19Upgrade Guggenheim Neutral → Buy
Nov-26-18Initiated JP Morgan Overweight $35
Nov-07-18Reiterated B. Riley FBR Sell $20 → $21
Nov-07-18Downgrade William Blair Outperform → Mkt Perform
Oct-12-18Reiterated H.C. Wainwright Buy $33 → $29
Oct-10-18Initiated Guggenheim Neutral
Sep-07-18Initiated Cowen Sell $20
Sep-07-18Initiated B. Riley FBR Sell $20
Aug-21-18Initiated Citigroup Neutral $40
Jun-26-18Initiated Chardan Capital Markets Neutral $35
Feb-13-18Initiated Mizuho Neutral $26
Dec-20-17Initiated H.C. Wainwright Buy $37
Oct-17-17Initiated William Blair Outperform
Oct-16-17Downgrade Evercore ISI Outperform → In-line
Oct-12-17Initiated Raymond James Mkt Perform
Aug-17-17Initiated Evercore ISI Outperform $23
May-01-17Initiated Leerink Partners Outperform
Feb-13-19 08:20AM  Report: Developing Opportunities within Dunkin' Brands Group, Murphy Oil, NII, Audentes Therapeutics, RealNetworks, and MDC Partners Future Expectations, Projections Moving into 2019 GlobeNewswire
Feb-08-19 06:00PM  Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Feb-05-19 02:25PM  Mizuho's 9 Best Biotech Stocks to Buy for 2019 Kiplinger
Jan-31-19 08:00AM  Audentes Therapeutics Announces Next Steps in the Development of AT132 to Treat XLMTM Following Collaborative Initial Meeting with FDA Under RMAT Designation PR Newswire
Jan-07-19 08:00AM  Audentes Therapeutics Reports on Recent Progress and Outlines 2019 Key Priorities PR Newswire +6.63%
Jan-04-19 06:00PM  Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Jan-03-19 08:00AM  Audentes Therapeutics Appoints Eric B. Mosbrooker as Senior Vice President and Chief Commercial Officer PR Newswire
Jan-02-19 08:00AM  Audentes Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-21-18 10:11AM  Need To Know: Audentes Therapeutics, Inc. (NASDAQ:BOLD) Insiders Have Been Selling Shares Simply Wall St.
Dec-18-18 01:33AM  Is Audentes Therapeutics, Inc. (BOLD) Going to Burn These Hedge Funds? Insider Monkey -5.70%
Dec-13-18 05:18PM  Targeting 'bubble baby' disease, this gene therapy company is planting a flag in the East Bay American City Business Journals
Dec-07-18 06:00PM  Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Nov-19-18 09:51PM  Edited Transcript of BOLD earnings conference call or presentation 6-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Nov-12-18 04:21PM  These Biopharmas Could Cure Genetic Diseases At $5 Million Apiece Investor's Business Daily
Nov-09-18 08:55AM  Recent Analysis Shows Audentes Therapeutics, Endocyte, Bluerock Residential Growth REIT, Air Products and Chemicals, BWX Technologies, and Modine Manufacturing Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-07-18 08:00AM  Audentes Therapeutics to Participate in Upcoming Investor Conferences PR Newswire -18.03%
Nov-06-18 04:21PM  Audentes Therapeutics: 3Q Earnings Snapshot Associated Press
04:01PM  Audentes Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update PR Newswire
Nov-05-18 08:00AM  Audentes Therapeutics Board of Directors Appoints Co-Founder and Chief Executive Officer Matthew R. Patterson as Chairman PR Newswire
Oct-30-18 08:00AM  Audentes Therapeutics to Release Third Quarter 2018 Financial Results and Provide Corporate Update on Tuesday, November 6, 2018 PR Newswire
Oct-16-18 07:36AM  Report: Developing Opportunities within The Ensign Group, Forterra, Inc., Audentes Therapeutics, Assembly Biosciences, Capital Senior Living, and Myomo Future Expectations, Projections Moving into 2018 GlobeNewswire
Oct-10-18 08:30PM  Audentes Therapeutics Announces Pricing of Public Offering of Common Stock PR Newswire -18.73%
07:56AM  The Daily Biotech Pulse: Novartis Blood Disorder Drug Improves Patient Outcomes, Audentes To Offer Shares Benzinga
Oct-09-18 04:20PM  Audentes Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
Oct-08-18 02:50PM  Meet the $172.5 million biotech IPO from the U.K. with big plans to grow in the Bay Area American City Business Journals
10:07AM  Audentes Therapeutics (BOLD) Catches Eye: Stock Jumps 7% Zacks
Oct-05-18 05:20PM  Meet the $172.5 million biotech IPO from the U.K. with big plans to grow in the Bay Area American City Business Journals +7.01%
08:01AM  Audentes Therapeutics to Provide Update on New Positive Interim Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy, from the 23rd International Annual Congress of the World Muscle Society PR Newswire
08:00AM  Audentes Therapeutics Presents New Positive Interim Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy, at 23rd International Annual Congress of the World Muscle Society PR Newswire
Sep-26-18 08:00AM  Audentes Therapeutics to Participate in Upcoming Investor Conferences PR Newswire
Sep-24-18 08:00AM  Audentes Therapeutics to Present New Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy, at the 23rd International Congress of the World Muscle Society PR Newswire
Sep-06-18 02:17PM  Edited Transcript of BOLD earnings conference call or presentation 7-Aug-18 12:00pm GMT Thomson Reuters StreetEvents
Aug-29-18 08:00AM  Audentes Therapeutics to Participate in Upcoming Investor Conferences PR Newswire
Aug-21-18 08:00AM  Audentes Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by the FDA to AT132 for the Treatment of X-Linked Myotubular Myopathy PR Newswire
Aug-17-18 07:50AM  Factors of Influence in 2018, Key Indicators and Opportunity within AgroFresh Solutions, SMART SAND INC, Advantage Oil & Gas, Abeona Therapeutics, B. Riley Financial, and Audentes Therapeutics New Research Emphasizes Economic Growth GlobeNewswire
Aug-09-18 08:00AM  Audentes Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference PR Newswire
Aug-08-18 03:10PM  Backed with $140M, startup launches three-pronged attack on liver diseases American City Business Journals +5.94%
11:41AM  Mizuho Upgrades Audentes On Promising Gene Therapy Candidate Benzinga
Aug-07-18 06:25AM  Audentes Therapeutics: 2Q Earnings Snapshot Associated Press -9.82%
06:00AM  Audentes Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
06:00AM  Audentes Therapeutics Reports Second Quarter 2018 Financial Results and Provides Update on ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy PR Newswire
Jul-31-18 08:00AM  Audentes to Release Second Quarter 2018 Financial Results and Provide Update on ASPIRO, the Phase 1/2 study of AT132 in Patients with X-Linked Myotubular Myopathy PR Newswire
Jul-20-18 09:30AM  Is Audentes Therapeutics (BOLD) Stock Outpacing Its Medical Peers This Year? Zacks
Jun-26-18 07:10AM  Free Technical Reports on Array BioPharma and Three Additional Biotech Equities ACCESSWIRE
Jun-05-18 08:00AM  Audentes Announces Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to AT132 for the treatment of X-Linked Myotubular Myopathy PR Newswire
May-31-18 08:25AM  Market Trends Toward New Normal in Audentes Therapeutics, Aqua Metals, BT Group, Mid-America Apartment Communities, MDC Partners, and Hexcel Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
May-29-18 08:00AM  Audentes Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference PR Newswire
May-28-18 08:02AM  Edited Transcript of BOLD earnings conference call or presentation 9-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-18-18 07:05AM  Audentes Therapeutics and Three More Stocks Under Scanner in the Biotech Space ACCESSWIRE -7.61%
May-16-18 11:30AM  Audentes Announces Continuing Positive Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular Myopathy PR Newswire
May-10-18 07:25AM  Wired News - Ascendis Pharma Dosed First Subjects in First-in-Human Phase-1 Trial of TransCon CNP ACCESSWIRE -9.05%
May-09-18 04:43PM  Audentes Therapeutics: 1Q Earnings Snapshot Associated Press
04:01PM  Audentes Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update PR Newswire
11:23AM  What Should We Expect From Audentes Therapeutics Incs (NASDAQ:BOLD) Earnings In The Next Couple Of Years? Simply Wall St.
08:00AM  Audentes Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference 2018 PR Newswire
May-08-18 08:00AM  Audentes Therapeutics Announces the Promotion of Natalie Holles to President and Chief Operating Officer PR Newswire
May-02-18 08:00AM  Audentes Therapeutics to Release First Quarter 2018 Financial Results and Provide Corporate Update on Wednesday, May 9, 2018 PR Newswire
Apr-30-18 01:14PM  Audentes Therapeutics Announces Presentation of Data at the 21st Annual Meeting of the American Society of Gene and Cell Therapy PR Newswire
Apr-05-18 08:30AM  New Research: Key Drivers of Growth for Aqua Metals, Audentes Therapeutics, Gaming and Leisure Properties, Mammoth Energy Services, Inc., ONE Gas, and Mettler-Toledo International Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Mar-30-18 01:26PM  Edited Transcript of BOLD earnings conference call or presentation 8-Mar-18 9:30pm GMT Thomson Reuters StreetEvents
Mar-08-18 04:25PM  Audentes Therapeutics reports 4Q loss Associated Press
04:01PM  Audentes Therapeutics Reports Fourth Quarter 2017 and Full Year Financial Results and Provides Corporate Update PR Newswire
01:00PM  Audentes Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-07-18 08:46AM  Is a Surprise Coming for Audentes Therapeutics (BOLD) This Earnings Season? Zacks
07:35AM  New Research: Key Drivers of Growth for Entergy, CarMax, Verifone, Audentes Therapeutics, EZCORP, and Cabot Microelectronics Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Mar-06-18 08:00AM  Audentes Therapeutics to Present at the Cowen 38th Annual Health Care Conference PR Newswire
Mar-01-18 08:00AM  Audentes Therapeutics to Release Fourth Quarter and Full Year 2017 Financial Results and Provide Corporate Update on Thursday, March 8, 2018 PR Newswire
Feb-28-18 08:00AM  Audentes Therapeutics Joins Global Organizations In Recognizing Rare Disease Day® 2018 PR Newswire
Feb-12-18 08:00AM  Audentes Therapeutics Announces Dosing of First Patient in VALENS, a Phase 1/2 Clinical Trial of AT342 for the treatment of Crigler-Najjar Syndrome PR Newswire
Feb-08-18 08:00AM  Audentes Therapeutics to Present at the LEERINK Partners 7th Annual Global Healthcare Conference PR Newswire -7.92%
Feb-06-18 07:30PM  Audentes Therapeutics Announces Selection of Optimized Clinical Development Candidate for Pompe Disease Program PR Newswire
Jan-29-18 04:01PM  Audentes Therapeutics Announces the Closing of its Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares PR Newswire
Jan-24-18 07:43PM  Audentes Therapeutics Announces Pricing of Public Offering of Common Stock PR Newswire
Jan-23-18 04:01PM  Audentes Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
Jan-05-18 08:56AM  Audentes Therapeutics (BOLD) Jumps: Stock Rises 14.9% Zacks -10.25%
Jan-04-18 04:38PM  Biotech Stock Rockets To Record On Gene Therapy Trial In Children Investor's Business Daily +14.86%
12:30PM  Audentes Therapeutics Pulls Off Positive Interim Results 24/7 Wall St.
07:00AM  Audentes Announces Positive Interim Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular Myopathy PR Newswire
Jan-03-18 08:00AM  Audentes Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-13-17 08:00AM  Audentes Therapeutics Appoints Mark A. Goldberg, M.D. to its Board of Directors PR Newswire
Dec-07-17 08:25AM  Edited Transcript of BOLD earnings conference call or presentation 14-Nov-17 9:30pm GMT Thomson Reuters StreetEvents +5.32%
Nov-21-17 08:00AM  Audentes Therapeutics Announces Publication of Data from RECENSUS, a Retrospective Medical Record Review of Patients With X-Linked Myotubular Myopathy PR Newswire
Nov-16-17 08:00AM  Audentes Therapeutics to Present at Upcoming Investor Conferences PR Newswire +5.79%
05:14AM  Audentes Therapeutics reports 3Q loss Associated Press
Nov-14-17 04:01PM  Audentes Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update PR Newswire
12:00PM  Audentes Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Nov-07-17 08:00AM  Audentes Therapeutics to Release Third Quarter 2017 Financial Results and Provide Corporate Update on Tuesday, November 14, 2017 PR Newswire
Oct-13-17 12:09PM  How Spark's Gene Therapy Win Could Also Be A Boon For These Biotechs Investor's Business Daily
Sep-27-17 04:07PM  This Biotech Makes Bold Move On Potential For Speedier Drug OK Investor's Business Daily
08:00AM  Audentes Therapeutics Announces Rare Pediatric Disease and Fast Track Designations for AT132 for the Treatment of X-Linked Myotubular Myopathy PR Newswire
Sep-21-17 08:00AM  Audentes Therapeutics Announces Dosing of First Patient in ASPIRO, a Phase 1/2 Clinical Trial of AT132 for the Treatment of X-Linked Myotubular Myopathy PR Newswire
Sep-19-17 08:00AM  Audentes Therapeutics to Present at Upcoming Investor Conferences PR Newswire
Sep-05-17 07:40AM  Featured Company News Acorda Therapeutics Adopts Poison Pill ACCESSWIRE
Aug-10-17 11:54PM  Audentes Therapeutics reports 2Q loss Associated Press -15.34%
08:00AM  Audentes Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update PR Newswire
Jul-18-17 08:00AM  Audentes Therapeutics Announces Appointment of Fulvio Mavilio, Ph.D. to Vice President Scientific Affairs, Europe PR Newswire
Jun-28-17 08:00AM  Audentes Therapeutics Announces Participation in Upcoming Investor Conferences PR Newswire
Jun-13-17 08:00AM  Audentes Therapeutics Appoints Jennifer Jarrett to Board of Directors PR Newswire +7.01%
May-19-17 08:31AM  Why Audentes Therapeutics (BOLD) Could Be Positioned for a Surge Zacks
May-11-17 08:10AM  Audentes Therapeutics reports 1Q loss Associated Press
Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. Audentes Therapeutics, Inc. has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. The company was founded in 2012 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Holles Natalie C.President and COOJan 24Option Exercise2.768,30022,94933,390Jan 25 07:28 PM
LANGE LOUIS GDirectorDec 24Sale18.5312,000222,365558Dec 27 05:43 PM
LANGE LOUIS GDirectorDec 24Sale18.6720,000373,434325,799Dec 27 05:43 PM
Patterson Matthew RChief Executive OfficerDec 06Option Exercise0.7840,00031,20055,000Dec 10 04:39 PM
LANGE LOUIS GDirectorNov 15Sale22.494,00089,9603,555Nov 16 06:34 PM
LANGE LOUIS GDirectorNov 15Sale22.4920,000449,800345,799Nov 16 06:34 PM
Patterson Matthew RChief Executive OfficerOct 01Option Exercise0.7821,00016,38023,078Oct 02 07:04 PM
PRASAD SUYASHSenior VP & Chief Med OfficerOct 01Option Exercise0.7910,0007,9004,699Oct 02 07:05 PM
Patterson Matthew RChief Executive OfficerOct 01Sale38.1621,000801,37215,000Oct 02 07:04 PM
PRASAD SUYASHSenior VP & Chief Med OfficerOct 01Sale36.8810,000368,7880Oct 02 07:05 PM
GRAY JOHN T.SVP, Chief Scientific OfficerSep 28Option Exercise1.05879187Oct 02 07:03 PM
GRAY JOHN T.SVP, Chief Scientific OfficerSep 28Sale40.00873,4800Oct 02 07:03 PM
Patterson Matthew RChief Executive OfficerSep 24Option Exercise0.7815,00011,70015,000Sep 24 06:12 PM
LANGE LOUIS GDirectorSep 24Sale37.4113,000486,3191,558Sep 26 07:00 PM
LANGE LOUIS GDirectorSep 24Sale37.3520,000747,061365,799Sep 26 07:00 PM
Patterson Matthew RChief Executive OfficerSep 18Option Exercise2.1912,95228,36512,952Sep 20 07:01 PM
Patterson Matthew RChief Executive OfficerSep 18Sale40.0012,952518,0800Sep 20 07:01 PM
Patterson Matthew RChief Executive OfficerJul 05Option Exercise0.7823,14718,05523,147Jul 05 06:34 PM
Patterson Matthew RChief Executive OfficerJul 05Sale40.0423,147926,8520Jul 05 06:34 PM
Patterson Matthew RChief Executive OfficerJul 03Option Exercise0.7826,90120,98326,901Jul 05 06:34 PM
Patterson Matthew RChief Executive OfficerJul 03Sale40.0526,9011,077,4600Jul 05 06:34 PM
Patterson Matthew RChief Executive OfficerJul 02Option Exercise0.7821,00016,38019,599Jul 05 06:34 PM
PRASAD SUYASHSenior VP & Chief Med OfficerJul 02Option Exercise0.7910,0007,9005,011Jul 05 06:35 PM
PRASAD SUYASHSenior VP & Chief Med OfficerJul 02Sale38.4110,000384,0670Jul 05 06:35 PM
Patterson Matthew RChief Executive OfficerJul 02Sale38.3621,000805,5240Jul 05 06:34 PM
NEWMAN MARYSVP, Regulatory AffairsJun 25Option Exercise2.198,54518,6738,245Jun 27 06:52 PM
NEWMAN MARYSVP, Regulatory AffairsJun 25Sale40.798,545348,5810Jun 27 06:52 PM
LANGE LOUIS GDirectorJun 25Sale40.8613,000531,1542,558Jun 27 06:51 PM
LANGE LOUIS GDirectorJun 25Sale40.4220,000808,344385,799Jun 27 06:51 PM
Nagler DavidSVP, HR & Corp. AffairsJun 20Option Exercise2.195,00010,9264,700Jun 22 07:11 PM
Nagler DavidSVP, HR & Corp. AffairsJun 20Sale45.295,000226,4610Jun 22 07:11 PM
Holles Natalie C.President and COOJun 01Option Exercise2.765,09014,07325,090Jun 04 04:48 PM
Patterson Matthew RPresident & CEOMay 21Option Exercise0.7820,30015,83413,600May 23 06:13 PM
Patterson Matthew RPresident & CEOMay 21Sale38.1520,300774,4980May 23 06:13 PM
Patterson Matthew RPresident & CEOApr 02Option Exercise0.78700546700Apr 04 09:01 PM
Patterson Matthew RPresident & CEOApr 02Sale30.0170021,0090Apr 04 09:01 PM
PRASAD SUYASHSenior VP & Chief Med OfficerMar 29Option Exercise0.797,8006,1627,800Mar 29 08:23 PM
PRASAD SUYASHSenior VP & Chief Med OfficerMar 27Option Exercise0.79300237300Mar 28 09:12 PM
PRASAD SUYASHSenior VP & Chief Med OfficerMar 26Option Exercise0.791,9001,5011,900Mar 28 09:12 PM
PRASAD SUYASHSenior VP & Chief Med OfficerMar 26Sale30.001,90057,0000Mar 28 09:12 PM
LANGE LOUIS GDirectorMar 26Sale28.6228,000801,4733,558Mar 28 09:11 PM
LANGE LOUIS GDirectorMar 26Sale29.2720,000585,464405,799Mar 28 09:11 PM
NEWMAN MARYSVP, Regulatory AffairsMar 15Option Exercise2.1910,00021,9005,524Apr 02 09:06 PM
NEWMAN MARYSVP, Regulatory AffairsMar 15Sale30.3610,000303,6270Apr 02 09:06 PM
ORBIMED ADVISORS LLC10% OwnerMar 12Sale34.9918,003629,8593,539,997Mar 12 06:16 PM
ORBIMED ADVISORS LLC10% OwnerMar 09Sale35.6380,0002,850,0103,558,000Mar 12 06:16 PM
ORBIMED ADVISORS LLC10% OwnerMar 08Sale34.0658,4281,990,0583,638,000Mar 12 06:16 PM
ORBIMED ADVISORS LLC10% OwnerMar 06Sale33.0311,372375,6173,696,428Mar 06 05:53 PM
ORBIMED ADVISORS LLC10% OwnerMar 05Sale36.062007,2123,707,800Mar 06 05:53 PM
ORBIMED ADVISORS LLC10% OwnerMar 02Sale35.17421,63814,827,7873,708,000Mar 06 05:53 PM